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ABSTRACT: Angucyclines are a structurally diverse class of
actinobacterial natural products defined by their varied polycyclic
ring systems, which display a wide range of biological activities. We
recently discovered lugdunomycin (1), a highly rearranged
polyketide antibiotic derived from the angucycline backbone that
is synthesized via several yet unexplained enzymatic reactions.
Here, we show via in vivo, in vitro, and structural analysis that the
promiscuous reductase LugOII catalyzes both a C6 and an
unprecedented C1 ketoreduction. This then sets the stage for the
subsequent C-ring cleavage that is key to the rearranged scaffolds
of 1. The 1.1 Å structures of LugOII in complex with either ligand
8-O-Methylrabelomycin (4) or 8-O-Methyltetrangomycin (5) and
of apoenzyme were resolved, which revealed a canonical Rossman
fold and a remarkable conformational change during substrate capture and release. Mutational analysis uncovered key residues for
substrate access, position, and catalysis as well as specific determinants that control its dual functionality. The insights obtained in
this work hold promise for the discovery and engineering of other promiscuous reductases that may be harnessed for the generation
of novel biocatalysts for chemoenzymatic applications.
■ INTRODUCTION
Angucyclines represent by far the largest group of polycyclic
aromatic polyketides, which are rich in structural features, and
show diverse biological profiles, predominantly anticancer and
antibacterial.1 As exemplified by the promising angucycline
drugs landomycin,2 urdamycin,3 jadomycin,4 and gilvocarcin,5
angucyclines have been attractive targets for synthetic organic
chemistry as well as for biological activity studies. Inves-
tigations into their biosynthesis led to the discovery of novel
angucyclines, including new catalytic mechanisms and
enzymology.6,7 The Gram-positive Actinobacteria are a major
source of bioactive natural products, the majority of which are
produced by members of the genus Streptomyces.8,9 Despite the
increasing difficulty to isolate novel bioactive metabolites,
Streptomycetes still have a huge biosynthetic potential.10,11 This
is due to the fact that many of the biosynthetic gene clusters
(BGCs) are poorly expressed in the laboratory, generally
referred to as silent or cryptic BGCs.12,13 One such cryptic
BGC is that for the antibiotic lugdunomycin (1), an
angucycline-derived polyketide produced by Streptomyces sp.
QL37. Lugdunomycin has antibiotic activity against Gram-
positive bacteria, with an MIC of around 25 μg mL−1 against
Bacillus subtilis.14 The molecule has an unprecedented complex
skeleton, composed of a heptacyclic ring, a spiroatom, a
benzaza[4,3,3]propellane moiety, and two all-carbon stereo-
centers.14 The backbone of 1 is generated from acetate and
malonate subunits by the iterative action of a type II polyketide
synthase (PKS). The early biosynthetic steps yield the core
structure UWM6 (2) or prejadomycin (3), which undergoes
early stage tailoring reactions and is converted to 8-O-
methylrabelomycin (4) and then 8-O-methyltetrangomycin
(5) and tetrangulol methyl ether (6), which then serve as the
key intermediates for the subsequent Baeyer−Villiger oxidation
at the C6a−C7 bond of ring C (Scheme S1). Structural
rearrangement and the introduction of a nitrogen atom afford
limamycins, which react in a cascade of oxidative C−C bond
cleavage and aldol condensation, leading to the production of
iso-maleimycin.15 Finally, the Diels−Alder [4 + 2] cyclo-
addition step between iso-maleimycin and the hydroxy-o-
quinodimethane intermediate resulted in the generation of 1.
In addition to 1, 11 newly rearranged and nonrearranged
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angucyclines featuring diverse patterns were discovered. In
light of the intriguing ring cleavages, aldol condensation, and
Diels−Alder cycloaddition, the lug gene cluster presents a
unique opportunity to study the versatile post-PKS tailoring
reactions.
The lug gene cluster (Figure S1) encodes a minimal PKS
complex, regulators, transporters, and a series of post-PKS
tailoring enzymes, including oxygenases, reductases and group
transferases. The role of the minimal PKS in the production of
the angucycline backbone has been well studied in many
families of the angucycline antibiotics.1,7 However, under-
standing the enzymology behind the chemical transformations
is needed to expand our knowledge of lugdunomycin (1)
biosynthesis. Reductases, as one of the most powerful synthetic
chemical transformants, have been employed by introducing
complex chiral centers in natural products. The archetypal
example is ActKR, a regio- and stereospecific C9 ketoreductase
in the synthesis of the antibiotic actinorhodin, in which single
mutations could convert stereospecificity to either an R- or S-
dominant product.16 Another widely studied example is LanV,
which carries out a C6 ketoreduction during the biosynthesis
of landomycins, a promising group of anticancer agents.17,18
The stereochemical outcomes of LanV are controlled more by
the conformational changes of the substrate, rather than by the
enzyme itself.17,18 Structural studies of the ketoreductases
revealed typical Rossman folds that are shared by the short-
chain alcohol dehydrogenase/reductase (SDR) family of
enzymes.16,19 Investigations into the active site architecture
highlighted differences in substrate specificity and the stereo-
chemical outcome of the ketoreduction of LanV compared to
UrdMred, PgaMred, and CabV.17,18
Herein, we describe the identification and characterization of
LugOII as a promiscuous ketoreductase that plays a key role in
lugdunomycin (1) biosynthesis. We determined the crystal
structure of LugOII bound to its substrates and, specifically,
revealed the structural changes in the enzyme during catalysis.
Mutational analysis of the active site provided details on
unique features contributing to its dual functionality. These
data expand our understanding of LugOII in generating a great
diversity of angucycline analogs.
■ RESULTS AND DISCUSSION
Identification of LugOII, an Atypical Reductase in the
Lugdunomycin Pathway. We explored the enzymatic basis
for the observed chemical transformations leading to the
production of lugdunomycin (1) (Figure 1). The lug gene
cluster encodes polyketide synthases and putative oxygenases
and reductases (Figure S1). A comparison of the lug gene
cluster with the related gene clusters pga (gaudimycin), urd
(urdamycin), lan (landomycin), and jad (jadomycin) revealed
that lugA-lugF are the minimal PKS genes required for the
biosynthesis of 2, the first stable angucycline intermediate14
(Scheme S1). Subsequent spontaneous dehydration should
then result in 3. LugM encodes a methyltransferase, which is
likely to be involved in the methylation of 2 and/or 3.14 A C12
hydroxylation then takes place in the next step by the FAD-
binding oxygenase LugOI, which is a homologue of PgaE,
UrdE,20 and LanE.21 Additionally, we identified LugOII, which
consists of two domains, an N-terminal FAD-binding
flavoprotein domain and a C-terminal SDR domain. The
enzyme shares over 60% amino acid identity with UrdM,
PgaM, LanM2,22 and BexM,23 which are encoded by the BGCs
of urdamycin, gaudimycin, landomycin, and BE-7585A,
respectively (Figures S3 and S4). The reductase domains of
UrdM and PgaM21,24 catalyze a C6 ketoreduction. The high
similarity between the reductase domains of LugOII, UrdM,
Figure 1. Structures of the metabolites discussed in this study. Lugdunomycin (1), UWM6 (2), prejadomycin (3), 8-O-methylrabelomycin (4), 8-
O-methyltetrangomycin (5), tetrangulol methyl ether (6), 1-deoxo-1-hydroxy-8-O-methylrabelomycin (7), SM-196B (8), and 12-deoxo-12-
hydroxy-8-O-methyltetrangomycin (9).
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and PgaM suggests that LugOII may carry out a reduction at
C6 after the action of LugOI. Thus, we set out to study the
function of LugOII in lugdunomycin biosynthesis.
Besides a start codon at the beginning of the gene, lugOII
also possesses an internal start codon at about two-thirds of the
gene, suggesting a nested gene system, which was observed in
its homologue pgaM.25 To investigate the complex formation
of LugOII in vivo, we placed the entire lugOII gene under the
control of the constitutive and strong ermE* promoter in a
lugOII null mutant of Streptomyces sp. QL37. This indeed
resulted in the production of two protein forms that
corresponded in size to the 70 kDa full-length LugOII and
the 27 kDa LugOII reductase domain (Figure S2). Both
fragments were verified by liquid chromatography coupled to
mass spectrometry (LC-MS/MS).
LugOII Acts as a C6 Reductase during Lugdunomycin
Biosynthesis. To investigate the biosynthetic role of LugOII,
we constructed a lugOII null mutant (see Methods for details).
Streptomyces sp. QL37 and its lugOII null mutant were grown
on both R5 and on minimal media (MM) agar plates for 7
days, after which the agar was extracted with ethyl acetate
followed by LC-MS. 1 was only produced by the wild-type
strain on MM. Analysis of the LC-MS data revealed that on R5
agar the production of 5 and 6 (Figure 1) was abolished in
ΔlugOII, indicating an essential role of the enzyme in the
angucycline biosynthetic pathway (Data S1). The production
of 5 and 6 was restored in a complemented mutant that
expresses lugOII from the constitutive ermE* promoter.
Additionally, a peak corresponding to the previously described
12-deoxo-12-hydroxy-8-O-methyltetrangomycin (9)14 was ab-
sent in the metabolic extracts of ΔlugOII (Data S1A,B). The
production of the molecule was also restored in the
complemented mutant grown on R5. The absence of 5, 6,
and 9 in the deletion strain and their restoration in the
genetically complemented mutant expressing lugOII suggest
that LugOII may bear C6 reduction activity, which is
consistent with its similarity to enzymes carrying out similar
reactions. Notably, on MM, the production of 1 was abolished
in the deletion mutant, indicating that lugOII likely ensures the
production of precursors that are essential for its biosynthesis
(Data S1B). Colonies of the complemented mutant did not
grow well on MM, and the production of 1 in this strain was
therefore not evaluated. Conversely, the biosynthesis of 4,
which bears an oxidized C6, was not affected in lugOII mutants
grown on R5 or MM agar. On the basis of similar metabolites
observed in the biosynthetic pathways of gilvocarcin and
fluostatin angucyclines,26,27 the desmethyl derivative of 4
(rabelomycin) can be a spontaneous product of 2 and/or 3,
the key intermediates in angucycline biosynthesis.28,29
In Vitro Characterization Confirms That LugOII Is a
Promiscuous Reductase That Also Carries out C1
Reduction. To further explore the catalytic nature of LugOII,
compounds 4 and 5 were selected for an in vitro reaction with
the enzyme. Recombinant LugOII was purified to homoge-
neity, and enzymatic reactions were performed, followed by
extraction with ethyl acetate for LC-MS analysis. Incubation of
4 with LugOII resulted in the consumption of the substrate
and the appearance of 7 (Figure 2a,b). Meanwhile, the
enzymatic reaction of 5 with LugOII resulted in the production
of 8 (Figure 2c,d). The C1 ketone group in compounds 4 and
5 was proposed as the likely reduction site. Such reduction
would then result in angucycline derivatives that were
previously shown to be unstable and easily oxidized in the
presence of light.30 Accordingly, the enzymatic reactions were
performed in the dark. NMR analysis of the reaction product
of 4 resulted in the identification of 7 as the previously
reported angucycline 1-deoxy-1-hydroxy-8-O-methylrabelomy-
cin,31 which was also isolated earlier from Streptomyces sp.
QL3714 (Table S4, Data S2). Conversely, NMR analysis of the
reaction product of 5 resulted in the identification of 8 as the
previously reported angucycline SM 196 B30 (Table S4, Data
S3). The results confirmed that LugOII catalyzes a C1
reduction, which is a reaction that has not previously been
reported for this kind of enzyme.
X-ray Crystallography Reveals Dual Functionality of
LugOII. To understand the biochemistry of the C1 reduction
in high mechanical detail, we analyzed the structure of the
purified enzyme with and without substrates by X-ray
crystallography. For this, LugOII was overexpressed and
purified to homogeneity. Hexagonal and monoclinic crystals
allowed one to determine the structures of apo-LugOII (PDB
ID Code 6YQ6) and LugOII with NADPH (PDB ID Code
6YPZ) to 2.0 and 1.1 Å resolution, respectively. We also
resolved the crystal structures with the substrates 4 (1.5 Å,
PDB ID Code 6YQ3) and 5 (1.1 Å, PDB ID Code 6YQ0) to
obtain mechanistic insights into the enzymatic reaction in the
active site of the enzyme. Data acquisition and refinement
statistics are summarized in Table S3. Figure 3A presents a
stereoview of the NADPH-liganded structure, which adopts
the canonical Rossman fold, as seen in other homologous
enzymes. This is similar to, e.g., ActKR16 and UrdMred18 from
a type II polyketide synthase, TylKR19 from a type I polyketide
synthase, and FabG32 from a type II fatty acid synthase. The
same dimeric configuration is found in each asymmetric unit of
all four crystals. A sequence and structural homologue search33
indicated that LugOII belongs to the SDR and FabG
superfamily (Pfam 13561), characterized by a highly similar
α/β fold but with diverse functions.34
DALI33 superimposition of apo-LugOII with the NADPH-
liganded LugOII and with two substrates liganded to LugOII
resulted in a root-mean-square deviation of Cα positions
(RMSD) of around 1.1 Å (Figure 3B), while superimposition
of all ligand-bound structures retained an RMSD of 0.2−0.5 Å
(Figure 3C). The structure of NADPH-liganded LugOII differs
significantly from that of the apo-enzyme (Figure 3). In the
latter, a subdomain “lid” formed by the helices α6 and α7 and
the nearby loop region has closed down on the α/β-subdomain
of the enzyme. Flipping of α6 drives the rotation of α7 by
Figure 2. Extracted-ion chromatogram (XIC) overlay of the ion peaks
of all the related compounds from the in vitro reactions. Enzymatic
reactions: (a) 4; (b) 4 + LugOII; (c) 5; (d) 5 + LugOII. The
experiments were independently repeated three times with similar
results.
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∼90° toward the substrate binding site (Figure 3B), thereby
closing the active site pocket. This switches to an open
conformation upon binding of a cofactor and/or ligand and
stays open until the end of the reaction, as evidenced from the
alignment of all the structures in Figure 3. On the basis of the
sequence alignment (Figure S2) and on previous studies,35 the
α6−α7 motif is the least conserved region. Small conforma-
tional changes in this motif have been reported in many
homologous enzymes, such as ActKR,16 SimC7,36 and FabG.32
However, the large conformational change we report for
LugOII is rare in the KRs involved in natural product
biosynthesis, suggesting significant differences and a potential
benefit of shielding the active site residues in the absence of
NADPH.
As described above, our metabolomic data suggested that
compounds 4 and 5 are substrates for LugOII. Co-
crystallization of LugOII with 4 and 5 produced clear densities
for both ligands, except for the partially missing densities for
the A-ring of 4. Each ligand was bound in a deep crevice
(Figure 4A,B), which positions the substrate for catalysis
mainly through hydrophobic interactions. As can be seen in
Figure 4C,D, the NADPH nicotinamide, together with either 4
or 5, is perfectly aligned with the strictly conserved catalytic
triad Ser149−Tyr162−Lys166 that is seen in most natural
product ketoreductases (KRs).35 With a Cα RMSD of 0.1−0.5
Å, two substrate-bound structures showed high similarity,
indicating no significant conformational change during
catalysis. Compound 4 was bound in a similar way compared
to rabelomycin and 11-deoxylandomycinone that are found in
the structure of LanV (PDB ID 4KWI) and UrdMred (PDB
ID 4OSP) (Figures 4C and 6A,B), indicating a similar catalytic
mechanism of LugOII in terms of the C6 reduction. However,
compound 5 was oriented approximately 180° compared to
compound 4, thus positioning the C1 ketone group of 5
toward the catalytic triad, making it a perfect model for the
detailed analysis of the mechanism of C1 reduction (Figure
4E,F).
Figure 3. Dimeric arrangement of LugOII structures and observed conformational changes. (A) Stereoscopic view of NADPH-bound LugOII in
dimeric form. (B) Unliganded LugOII (green), LugOII/NADPH (cyan), LugOII/NADPH/4 (yellow), and LugOII/NADPH/5 (magenta)
structures are superimposed. α6, α7, and the loop region between them serve as a lid, which turn around 180° and then rotate 90° toward the
binding site of 5. (C) Alignment of LugOII/NADPH (cyan), LugOII/NADPH/4 (yellow), and LugOII/NADPH/5 (magenta) structures.
NADPH, 4, and 5 are displayed in sticks.
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As shown in Figure 5, the C1 ketone of 5 is hydrogen
bonded to both Ser149 and Tyr162 that constitute the
oxyanion hole. Attacking by the pro-4(S) proton from the
NADPH carbonyl from “above” yields a C1 alkoxide that is
stabilized by the hydrogen bonds of Ser149 and Tyr162. The
conserved Tyr162 residue serves as central acid−base catalyst
that donates a proton to the substrate, while the adjacent K166
residue lowers the pKa of the hydroxyl group of Tyr162, thus
contributing directly to the proton relay system. The hydroxyl
group of S149 stabilizes and polarizes the carbonyl group of
the substrate. The relative configuration of the two hydroxyl
groups at C1 and C3 was assigned as trans on the basis of the
electron densities and the position of 5 in the active sites of
LugOII (Figure 5). As the absolute configuration at C3 in
compound 5 was confirmed to be R by total synthesis,37 an S-
configuration could thus be assigned to C1. The reaction
mechanism of 4 to 7 could also be deduced similarly. The
catalytic mechanism of C1 reduction resembles that of C6
reduction that occurs in the other homologous enzymes LanV
and UrdMred18 but also differs in many ways, which are
discussed later.
Key Features in the Active Site of LugOII. Our
enzymatic and structural analyses highlight LugOII as a
promiscuous enzyme that catalyzes C1 reduction of both 4
and 5. We therefore wondered how both reactions could be
catalyzed by a single active site. On inspection of the two
substrate−liganded structures, movement of the α4−β4 loop
was observed not only in LugOII complexed with 4 and 5 but
also in different chains of one specific structure (Figure S6). As
shown in Figure 4F, the A-ring of 5 resides much more
downward than that of 4 to cover the A-ring, while the α4−β4
loop also adopts a more closed position. That is, the A-ring of
4 cannot fit into the “normal” pocket of 5. The same effect can
also be seen in LanV and UrdM18 complex structures, where
the A-ring of rabelomycin and 11-deoxylandomycinone
collapse in the “normal” pocket (Figure 6D). This movement
can be attributed to a steric effect, in other words, with the
movement as the driving force for substrate rotation. Notably,
the loop region in LugOII is extended by two residues (Val103
and Asp104) as compared to LanV and UrdM,18 and we
therefore hypothesize that this makes LugOII more dynamic.
Residues Cys154 and Ser214 at the end of the active site
replace residues Val152 and Leu212 in LanV (PDB ID 4KWI)
and Phe152 and Tyr212 in UrdMred (PDB ID 4OSP),
respectively. The bulkier residues that are found in LanV17 and
UrdMred18 structures decrease the volume of the active site,
which may act as “gatekeepers” that affect the substrate
rotation. Cys154 was found to adopt different confirmations in
both compound 4 and 5 complexed structures (Figure 4C,D).
Superimposition of 5 into the active cavity of UrdMred shows
a clash between the 8-O-methyl group of 5 and the phenyl
moiety of Phe152 (Figure 6C). Similarly, Thr101 in the
α4−β4 loop region of LugOII is replaced by a methionine in
its orthologues. Finally, the 2-methyl group of 5 and the 4-thio
group of M101 are at only a 1.0−1.7 Å distance, which should
sterically affect substrate rotation (Figure 6C).
Site-Directed Mutagenesis of Active Site Residues.
To validate the structural data, we probed the positions that
contain the α4−β4 loop region (Val103, Asp104) and the
active site residues (Cys154, Ser214, and Thr101). Val156,
Gln159, and Ile194 were also chosen, as they were predicted to
play important roles in LanV, UrdMred, and other KRs. To
investigate their roles in the dual function of LugOII, we
created site-directed mutants and expressed the protein
Figure 4. Active site of LugOII. (A, B) 2Fo − Fc omit maps contoured at the 1σ level corresponding to ligands 4 and 5 and cofactor NADPH. The
missing density for 4 is highlighted with a black circle. (C, D) Key residues that surround the binding site of 4 and 5. Catalytic residues Ser149,
Tyr162, and Lys166 are underlined, and their distances (within 3.2 Å) to the ligand and cofactor are dashed. (E, F) Superposition of the two
substrates 4 and 5 bounded to LugOII. (E) Top view of the active pocket. (F) Side view of the two aligned substrate structures. Major differences
are found in the orientations of the two substrates and the movement of the α4−β4 loop that are close to the A-rings of the two substrates. See also
Figure S6.
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variants for in vitro enzymatic assays. While residues Val103
and Asp104 were deleted, Cys154, Ser214, and Thr101 were
mutated to the bulkier residues Phe, Tyr, and Met,
respectively. Furthermore, Val156 and Gln159 were sub-
stituted by alanine, and Ile194 was substituted by a serine
residue.
Enzymatic activity was measured through the relative
NADPH consumption rate by UV absorption scanning at
340 nm, using 5 as the precursor in the reaction (Figure 7).
The V156A, C154F, ΔV103, and S214Y mutants showed
similar NADPH consumption rates compared to the wild-type
enzyme (Figure 7), indicating that these residues did not play a
role in LugOII activity. In the mutant lacking Val103 and
Asp104 in the α4−β4 loop region, the conversion rate was
slightly reduced (Figure 7). Conversely, the conversion rate of
5 was greatly reduced in mutant Q159A. The glutamine
residue in the equivalent site of LanV17 and UrdM18 interacts
with the ligand, while in LugOII, it acts as an anchor point for
the correct positioning of the α4−β4 loop (Figure S7). A
similar effect was seen in the T101 M mutant, where the
conversion rate was dramatically decreased. As T101 interacts
with the 3-hydroxyl group of compounds 4 and 5 (Figures S5
and S7), the mutation to methionine has less effect on ligand 4
but clashes with ligand 5 (Figure 6A,C). Clearly, the
substitution of Ile194 by a serine has a strong influence on
the catalytic activity of the C1 reduction (Figure 6A,C), which
supports the essential role of the equivalent isoleucine residue
in LanV17 and UrdM,18 in terms of substrate specificity and
stereoselectivity. These data highlight the key role of Thr101,
Gln159, and Ile194 plus the motion of the α4−β4 loop in the
dual functionality of LugOII, which is consistent with the
analysis of ligand 4 and 5 bounded structures.
In summary, combined mutational, enzymatic, and structural
analysis shows that besides the C6 ketoreduction, LugOII also
possesses an unprecedented C1 ketoreduction, generating the
two angucycline derivatives 7 and 8. The apo- and complexed
structures of LugOII shed light on several novel features near
the active center. A significant conformational change occurs
prior to catalysis, which is mainly achieved by flipping of the
α6−α7 motif. Additionally, mutagenesis showed that residue
Thr101 stabilizes the orientation of the substrate via a
hydrogen bond, leaving sufficient space to allow the entry of
different substrates (compounds 4 and 5) for the catalysis of
C1 reduction. The loop region that harbors Thr101 is also of
importance to the catalytic activity of LugOII, as the activity
was slightly decreased in mutants lacking Val103 and Asp104.
Furthermore, the mutation of Gln159, which mediates the
localization of the α4−β4 loop, led to a significant decrease in
the C1 reduction activity. It was also found that Ile194
contributes largely to the dual functionality of LugOII, which is
likely mediated via a hydrophobic interaction with the ligands.
Overall, our results provide new insights into the structure and
catalytic mechanism of a novel promiscuous reductase in
angucycline biosynthesis. Since angucyclines are one of the
most diverse and important families of polyketides, LugOII is a
promising candidate for its application in the synthesis of novel
regio- and stereochemically diverse polyketide antibiotics.
Figure 5. Postulated catalytic mechanism for the LugOII-catalyzed C1 reduction and proton relay. The reaction is initiated by proton transfer from
the hydroxyl group of Tyr162 to the carbonyl group of 5, followed by a hydride transfer to the C1 position of 5. The catalytic triad (Lys166,
Tyr162, and Ser149) and N123 are highlighted in blue.
ACS Chemical Biology pubs.acs.org/acschemicalbiology Articles
https://dx.doi.org/10.1021/acschembio.0c00564
ACS Chem. Biol. 2020, 15, 2529−2538
2534
■ METHODS
Strains, Mutants, and Genetic Complementation. Strepto-
myces sp. QL37 was isolated from the Qinling mountains in China.38
Strains were grown on MM or R5 agar plates.39 For details on strains
and culturing conditions, see the Supplemental Methods. An in-frame
deletion mutant of lugOII was obtained via homologous recombina-
tion.40 For generation of the knockout construct, the up- and
downstream (∼1.5 kb) regions of lugOII were amplified with the
primer pairs lugOII_LF_Fw/lugOII_LF_Rv and lugOII_RF_Fw/
lugOII_RF_Rv, respectively, from genomic DNA of Streptomyces sp.
QL37. The PCR products were cloned into the conjugative vector
pWHM3-oriT.41 The apramycin resistance cassette (aac(3)IV)
flanked with loxP sites was cloned between the upstream and
downstream region of lugOII. To obtain lugOII null mutants, the
plasmids were introduced into Streptomyces sp. QL37 via conjugative
transfer from E. coli ET12567/pUZ800239 and lawns of the
transformants replicated nonselectively to allow double recombina-
tion. In this way, a mutant was obtained whereby the chromosomal
lugOII was replaced by the apramycin resistance cassette. Cre
recombinase was expressed via introduction of plasmid pUWL-
Cre42 to remove the apramycin cassette, resulting in an in-frame
deletion mutant lacking the +12/+1947 region relative to the
translational start site of lugOII. The mutant was verified by PCR
and DNA sequencing.
For genetic complementation, lugOII was amplified using primers
lugOII_OE_Fw/lugOII_OE_Rv. The insert was placed under the
control of an ermE promoter. The integrity of the construct was
verified by sequencing. The plasmid was conjugated to Streptomyces
sp. QL37 and Streptomyces sp. QL37 (ΔlugOII) using E. coli
ET12567/pUZ800239 as the donor strain. Primers are listed in
Table S2.
Protein Crystallization, Data Collection, and Structure
Solution. To obtain protein for crystallization and enzymatic
experiments, LugOII was cloned into pET-28a (+) vector (Novagen).
LugOII active site mutants were generated by whole plasmid synthesis
(WHOPS) based on the instructions of Quik Change* Site-Directed
Mutagenesis (Stratagene). All constructs were sequenced before use.
The plasmid expressing LugOII was transformed into E. coli BL21
(DE3) pLysS Star (Invitrogen), and the N-terminal His6-tagged
protein was expressed and purified as described.43 All crystallization
experiments of LugOII were conducted with N-terminal His6-tag
(21.8 mg mL−1) by sitting-drop vapor diffusion at 18 °C. Monoclinic
apo-LugOII crystals (apo form) were obtained in 0.3 M NaCl, 0.1 M
Na cacodylate, pH 6.5, 1.5 M (NH4)2SO4. For cocrystallization,
NADPH was added to LugOII to a final concentration of 1 mM and
1/10 vol of a saturated solution of either 4 or 5. Brown color crystals of
both complex forms grew from the condition of 16−22% (w/v)
PEG3350, 0−0.1 M Na malonate, 0.1 M BIS-Tris prop, pH 6.5.
Crystals were cryoprotected by supplementing the crystallization
solution with 20% (v/v) PEG400 or ethylene glycol (EG).
Diffraction data were collected at the Swiss Light Source at
beamline X06DA (PXIII) and theNational Synchrotron Radiation
Research Center, Taiwan, respectively. The data were further indexed,
integrated using XDS,44 and scaled and merged using AIMLESS45
from the CCP4 package.46 Phases of all the LugOII structures were
solved by molecular replacement with MOLREP,47 using UrdMred18
(PDB entry 4OSP) as the template. The models of apo and complex
structures were completed by several iterations of manual building in
COOT48 and restrained refinement in REFMAC549 using isotropic B
factors. The PRODRG server50 was used to generate the coordinate
files for the ligand of the binary complex. Structures were finalized by
several rounds of TLS and restrained refinement in REFMAC5 and
validated using the wwPDB validation service.51 Residues were in the
most favored regions of the Ramachandran plot52 as determined by
PROCHECK.53 The resultant data collection, processing, and
refinement statistics are summarized in Table S3.
Enzymatic Reactions. For the enzymatic reaction with 4 or 5, the
reaction mixture (100 μL) containing LugOII buffer (25 mM Tris,
155 mM NaCl, 5% (w/v) glycerol, 20 mM β-mercaptoethanol, pH
7.5), compound 4 or 5 (∼100 μM), LugOII (2 μM), and NADPH (1
mM) was incubated at 30 °C for 30 min. A control reaction was
performed with heat-inactivated LugOII. The reactions were acidified
by HCl to pH 3−4 and extracted with ethyl acetate (3 × 100 μL).
Reaction products were checked by LC-MS and NMR as
described,14,54 followed by comparison with the literature. For details,
see the Supplemental Methods.
Figure 6. Superposition of LugOII (green for 4 and magenta for 5),
LanV (cyan, PDB entry, 4KWI), and UrdMred (yellow, PDB entry,
4OSP) reveals major differences in the active sites. (A, B) LugOII/4,
LanV, and UrdMred structures are aligned. (C) 5 is superposed in the
active pocket of LanV and UrdMred. Clashes were seen in two
regions (highlighted by circles). One region is the extra loop between
α4 and β4 in which Thr101 of LugOII is replaced by Met101 of LanV
and UrdMred. The other region represents residues Cys154 and
Ser214 that are near the D-ring binding site. They were substituted by
Val152 and Tyr212 in LanV and Phe152 and Leu212 in UrdMred,
respectively. (D) 11-Deoxylandomycinone of LanV and rabelomycin
of UrdMred are superposed in the LugOII active pocket, where
Val103 of LugOII clashes with the 3-methyl and 3-hydroxyl groups of
the A-ring, respectively.
Figure 7. Enzymatic activity of LugOII variants. The columns
represent the relative activity of LugOII variants compared to that of
the wild-type enzyme, based on the consumption rate of NADPH by
measuring the UV absorbance at 340 nm. Reactions were carried out
using compound 5 as the substrate. The experiments were
independently repeated three times with similar results.
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Metabolic Analysis. HPLC purifications were performed on a
Waters preparative HPLC system equipped with a photodiode array
detector (PDA). The absorption was monitored at 220, 290, and 350
nm. LC-MS analysis was performed on a Shimadzu LC-MS 9030
system composed of a UPLC with an attached PDA, coupled to a
QTOF HRMS, which uses ESI as an ionization source. NMR spectra
were acquired on a Bruker AVIII-600 NMR spectrometer (Bruker
BioSpin GmbH). For details on metabolite extraction and analysis,
see the Supplemental Methods.
■ ASSOCIATED CONTENT
*sı Supporting Information
The Supporting Information is available free of charge at
https://pubs.acs.org/doi/10.1021/acschembio.0c00564.
Supplemental methods for strains and culturing
conditions, metabolite isolation and characterization,
and LC-MS/MS methodology; graphical representation
of the lug gene cluster; SDS-PAGE analysis; multi-
sequence alignment of LugOII; unrooted maximum
likelihood tree of the KRs that are related to LugOII;
interactions between the ligands and the key residues of
LugOII structure; alignment of the different chains from
LugOII complex structures; interaction network of
Q159 in LugOII complex structures; supplemental
data and spectra; bacterial strains used in this study;
primers; X-ray data collection, processing, and refine-
ment; 1H and 13C NMR data (PDF)
Accession Codes
The atomic coordinates of the LugOII structures have been




Gilles P. van Wezel − Molecular Biotechnology, Leiden




Xiansha Xiao − Molecular Biotechnology, Leiden University,
2300RA Leiden, The Netherlands
Somayah S. Elsayed − Molecular Biotechnology, Leiden
University, 2300RA Leiden, The Netherlands; orcid.org/
0000-0003-3837-6137
Changsheng Wu − State Key Laboratory of Microbial
Technology, Institute of Microbial Technology, Shandong
University, Qingdao, Shandong 266237, P. R. China
Helga U. van der Heul − Molecular Biotechnology, Leiden
University, 2300RA Leiden, The Netherlands
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